Intravenous busulfan for allogeneic hematopoietic stem cell transplantation in infants: Clinical and pharmacokinetic results

Bone Marrow Transplantation

Volumn 32, Issue 7, 2003, Pages 647-651

  Dalle, J H ^a   Wall, D ^b   Theoret, Y ^a   Duval, M ^a   Shaw, L ^c   Larocque, D ^a   Taylor, C ^b   Gardiner, J ^c   Vachon, M F ^a   Champagne, Martin A ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

^b Methodist Children's Hospital of South Texas   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Allogeneic; Busulfan; Infants; Pharmacokinetics

Indexed keywords

ANTICONVULSIVE AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; MIDAZOLAM; MYELOABLATIVE AGENT; PHENYTOIN; THYMOCYTE ANTIBODY; URSODEOXYCHOLIC ACID;

AGE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AREA UNDER THE CURVE; ARTICLE; CHILD CARE; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG MEGADOSE; FEMALE; GAS CHROMATOGRAPHY; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFANT; LIVER VEIN OBSTRUCTION; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; ULTRAVIOLET RADIATION; VEIN OCCLUSION;

AREA UNDER CURVE; BUSULFAN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG EVALUATION; DRUG MONITORING; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; INFANT; INJECTIONS, INTRAVENOUS; MALE; PHARMACOKINETICS; RETROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 12444279063     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704209     Document Type: Article

References (28)

1. Fernandez HF et al. Evaluation of safety and pharmacokinetics of administering intravenous busulfan in a twice-daily or daily schedule to patients with advanced hematologic malignant disease undergoing stem cell transplantation. Biol Blood Marrow Transplant 2002; 8: 486-492.
2. Russell JA et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant 2002; 8: 468-476.
3. Santos GW et al. Marrow transplantation for acute non-lymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 1983; 309: 1347-1353.
4. Hartman AR, Williams S, Dillon JJ. Survival, disease-free survival and adverse effects of conditioning for allogeneic bone marrow transplantation with busulfan/cyclophosphamide vs total body irradiation: a meta-analysis. Bone Marrow Transplant 1998; 22: 439-443.
5. Bleyzac N et al. Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens. Bone Marrow Transplant 2001; 28: 743-751.
6. Yeager AM et al. Optimization of busulfan dosage in children undergoing bone marrow transplantation: a pharmacokinetic study of dose escalation. Blood 1992; 80: 2425-2428.
7. Tran HT et al. Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies. Bone Marrow Transplant 2000; 26: 463-470.
8. Sandstrom M et al. Population pharmacokinetic analysis resulting in a tool for dose individualization of busulphan in bone marrow transplantation recipients. Bone Marrow Transplant 2001; 28: 657-664.
9. Vassal G. Pharmacologically-guided dose adjustment of busulfan in high-dose chemotherapy regimens: rationale and pitfalls (review). Anticancer Res 1994; 14: 2363-2370.
10. Bolinger AM et al. An evaluation of engraftment, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic disease. Bone Marrow Transplant 2000; 25: 925-930.
11. Dupuis LL, Najdova M, Saunders EF. Retrospective appraisal of busulfan dose adjustment in children. Bone Marrow Transplant 2000; 26: 1143-1147.
12. Baker KS et al. Busulfan pharmacokinetics do not predict relapse in acute myeloid leukemia. Bone Marrow Transplant 2000; 26: 607-614.
13. Andersson BS et al. Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study. Biol Blood Marrow Transplant 2002; 8: 145-154.
14. Hassan Z et al. Pharmacokinetics of liposomal busulphan in man. Bone Marrow Transplant 2001; 27: 479-485.
15. Andersson BS et al. Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study. Biol Blood Marrow Transplant 2000; 6: 548-554.
16. Olavarria E et al. A phase I/II study of multiple-dose intravenous busulfan as myeloablation prior to stem cell transplantation. Leukemia 2000; 14: 1954-1959.
17. Wall D et al. Phase II trial of intravenous busulfan (Busulfex) with cyclophosphamide in pediatric allogeneic hematopoietic cell transplantation (HSC): pharmacokinetics, toxicity and efficacy (A Pediatric Blood and Marrow Transplant Consortium study). in: 42nd Annual Meeting of the American Society of Hematology Vol 97 edn. Hematology, A.S.o. (Blood, San Francisco, CA 2000.
18. Cremers S et al. Pharmacokinetics of intravenous busulfan in children prior to stem cell transplantation. Br J Clin Pharmacol 2002; 53: 386-389.
19. McDonald GB et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118: 255-267.
20. McDonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED. The clinical course of 53 patients with venocclusive disease of the liver after marrow transplantation. Transplantation 1985; 39: 603-608.
21. Lai WK et al. Routine analysis of plasma busulfan by gas chromatography-mass fragmentography. Clin Chem 1998; 44: 2506-2510.
22. Quernin MH et al. Quantification of busulfan in plasma by gas chromatography-mass spectrometry following derivatization with tetrafluorothiophenol. J Chromatogr B Biomed Sci Appl 1998; 709: 47-56.
23. Kaplan EL, Meir P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
24. Dix SP et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant 1996; 17: 225-230.
25. Vassal G, Gouyette A, Hartmann O, Pico JL, Lemerle J. Pharmacokinetics of high-dose busulfan in children. Cancer Chemother Pharmacol 1989; 24: 386-390.
26. Vassal G et al. Busulfan disposition below the age of three: alteration in children with lysosomal storage disease. Blood 1993; 82: 1030-1034.
27. Andersson BS et al. Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant 2002; 8: 477-485.
28. Hassan M, Oberg G, Bjorkholm M, Wallin I, Lindgren M. Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics. Cancer Chemother Pharmacol 1993; 33: 181-186.